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Abstract 
Given that many antifungal medications are susceptible to evolved resistance, there is a need for novel drugs with 
unique mechanisms of action. Inhibiting the essential proton pump Pma1p, a P‑type ATPase, is a potentially effective 
therapeutic approach that is orthogonal to existing treatments. We identify NSC11668 and hitachimycin as structur‑
ally distinct antifungals that inhibit yeast ScPma1p. These compounds provide new opportunities for drug discovery 
aimed at this important target.
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Background
Antifungal medications are in high demand, but low 
efficacy, host toxicity, and emerging resistance among 
clinical strains [1, 2] complicate their use. There is an 
urgent need for novel antimycotic therapeutics with 
unique mechanisms of action. The purpose of the cur-
rent work is to describe two novel antifungals: 4-N,6-
N-bis(3-chlorophenyl)-1-methylpyrazolo[3,4-d]
pyrimidine-4,6-diamine (NSC11668), and hitachimycin 
(also known as stubomycin, or NSC343256).
Most antifungals in clinical use target ergosterol, a 
sterol present in fungal membranes but largely absent 
from human cells [3]. Polyene antimycotics bind directly 
to ergosterol, thereby destabilizing the membrane [4]. 
Allylamines inhibit squalene monooxygenase [5], the 
first enzyme in the ergosterol biosynthetic pathway 
[6]. Most azole antifungals inhibit the downstream 
enzyme lanosterol 14 α-demethylase [7], with the pos-
sible exception of abafungin, which may instead affect 
sterol-C-24-methyltransferase and the fungal cell mem-
brane directly [8].
Only a few approved antimycotics have mecha-
nisms that are unrelated to ergosterol biosynthesis. 
For example, the highly effective echinocandins inhibit 
1,3-β-glucan synthase, hindering production of the criti-
cal cell-wall component β-glucan [9, 10]; and the terato-
genic compound flucytosine interferes with eukaryotic 
RNA/DNA synthesis [11, 12]. As these compounds act 
through pharmacologically distinct mechanisms, they 
can in principle complement anti-ergosterol interven-
tions (see, for example, Ref. [13]).
Recognizing the need for additional antifungals with 
mechanisms of action unrelated to ergosterol biosynthe-
sis, we turned our attention to the essential proton pump 
of the P-type ATPase class  (H+-ATPase), which is con-
served in both plants and fungi [14]. In the model organ-
ism S. cerevisiae, ScPma1p generates a proton gradient 
that is essential for both pH homeostasis and nutrient 
transport via  H+-symport. The resulting electrochemi-
cal gradient drives further nutrient uptake via uniporters 
[15]. A ScPMA1 null mutation is lethal in haploid cells, 
suggesting that the protein is essential for yeast survival 
[14].
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ScPma1p inhibitors are not necessarily toxic to humans 
[16, 17]. A BLASTP search using ScPma1p as the query 
sequence (UniProt P05030) revealed that the closest 
human homologs (calcium-transporting ATPases, e.g., 
UniProt O75185, A0A0A0MSP0, B7ZA13) share  ~  27% 
sequence identity. An antimalarial compound known to 
inhibit ScPma1p is also advancing through clinical trials, 
demonstrating that it is possible to develop ScPma1p-
specific small-molecule inhibitors with low host toxicity. 
ScPma1p is therefore an attractive target.
ScPma1p has at least three druggable pockets. The 
primary, orthosteric pocket binds ATP [18] and deca-
vanadate [19]. A second pocket—which binds the drug 
digoxin in the homologous  Na+,  K+-ATPase [20] —lies 
between the TM1 and TM4 transmembrane helices [21, 
22]. A third, cytoplasm-accessible pocket within the 
membrane-spanning domain binds spiroindolone [17] 
and tetrahydrocarbazole [23] inhibitors. Specific binding 
sites have not yet been validated for most ScPma1p inhib-
itors, including DMM-11 [24]; ebselen [25]; the natural 
products chebulagic acid and tellimagrandin II [26]; and 
the inhibitors found in a recent high-throughput screen 
[27]. Other molecules, such as the carbazole inhibitors 
[28] and demethoxycurcumin [29], do not compete with 
ATP binding and so must bind elsewhere. Whether these 
compounds bind the digoxin- or spiroindolone pockets 
remains unknown. Mutations near both these pockets 
also confer resistance to omeprazole, a covalent inhibitor 
with modest activity [30].
We recently discovered that KAE609, an antimalarial 
compound currently in Phase II clinical trials [16], is 
cytotoxic to S. cerevisiae and inhibits ScPma1p by bind-
ing to the cytoplasm-accessible pocket [17]. As part of 
a subsequent search for additional, structurally distinct 
ScPma1p inhibitors that bind to the same pocket, we 
used two different experimental assays (vesicular ScP-
ma1p and whole-cell yeast) to evaluate compounds avail-
able from the National Cancer Institute (NCI). These 
efforts unexpectedly identified two low-micromolar 
ScPma1p inhibitors, NSC11668 and hitachimycin, that 
apparently act via binding to one of the other ScPma1p 
pockets. We hypothesize that they target the nucleotide 
(ATP) binding site rather than the expected cytoplasm-
accessible pocket. We hope these leads will be useful in 
ongoing efforts to identify and optimize novel ScPma1p 
inhibitors.
Results and discussion
Identifying whole‑cell inhibitors
Motivated by the need for novel antimycotics that act 
orthogonally to existing antiergosterol therapeutics, 
we first sought to identify chemical compounds with 
whole-cell biological effects against fungi. S. cerevisiae 
is an excellent model organism representing this king-
dom, but its multiple drug efflux pumps often reduce the 
cytotoxicity of otherwise potent compounds. This yeast 
defense mechanism can lead researchers to discard mol-
ecules that might otherwise be potential leads if chemi-
cally optimized and/or coupled with adjuvants to prevent 
export. We therefore used the  ABC16-Monster yeast 
strain, which lacks 16 genes encoding ATP-binding cas-
sette (ABC) transporters [31] and so is more susceptible 
to cytotoxic compounds.
We experimentally screened the  ~  1500 compounds 
of the NCI Diversity Set IV, a repository of structur-
ally diverse, freely available small molecules, for activ-
ity against a whole-cell  ABC16-Monster culture. Of 
the ~ 1500 compounds tested, 36 inhibited yeast growth 
by at least 97% at 100 μM (Additional file 1: Table S1).
Confirming ScPma1p inhibition in a cell‑free assay
Using a computational protocol designed to predict 
small-molecule binding to the cytoplasm-accessible 
spiroindolone pocket, we selected seven of the whole-
cell inhibitors for further study. These compounds were 
tested for specific activity against ScPma1p in a vesicle-
based (cell-free) assay. In brief, we used a yeast strain 
that is prone to vesicle production due to an engineered 
defect in secretory-vesicle/plasma-membrane fusion. We 
transformed these yeast with a ScPMA1 overexpression 
plasmid, so the harvested vesicles bore high levels of ScP-
ma1p. ScPma1p inhibition was measured by monitoring 
ATP hydrolysis in the presence of the vesicles. Small-
molecule ScPma1p inhibitors prevented ATP hydrolysis, 
reducing the measured concentration of inorganic phos-
phate. See Ref. [17] for full details.
Two active compounds, NSC11668 and hitachimy-
cin, had  IC50 values of 4.4  μM and 7.8  μM in the cell-
free assay, respectively (Additional file  1: Figure S1A). 
These same compounds had  IC50 values of 14.8  ±  1.24 
(s.e.m) and 0.87  ±  0.11  μM against the whole-cell 
 ABC16-Monster strain (see Additional file  1: Figure S2, 
Rows A and B).
The compounds are unlikely to bind the 
cytoplasm‑accessible spiroindolone pocket
We tested both ScPma1p inhibitors (in duplicate) against 
the unmodified  ABC16-Monster strain, as well as against 
two  ABC16-Monster strains that each contained distinct 
spiroindolone-pocket ScPMA1 mutations: L290S and 
P399T (Additional file 1: Figure S3) [17]. As expected, the 
 IC50 values of NSC11668 and hitachimycin against the 
unmodified  ABC16-Monster strain were roughly equal 
to those found previously. As a positive control, we also 
tested KAE609, a known ScPma1p inhibitor that binds 
the cytoplasm-accessible (spiroindolone-binding) pocket. 
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It, too, had an unmodified-strain  IC50 comparable to that 
measured previously [17].
The positive control (KAE609) had a higher  IC50 
value when tested against the  ABC16-Monster strains 
with spiroindolone-pocket ScPMA1 mutations. This is 
expected; the mutations likely disrupt KAE609 bind-
ing, thereby reducing its potency. Given that our com-
putational protocol targeted the same ScPma1p pocket, 
we expected NSC11668 and hitachimycin  IC50 values 
to be similarly mutation dependent. But the  IC50 values 
of these inhibitors against the modified and unmodified 
 ABC16-Monster strains were roughly the same, suggest-
ing that the compounds do not bind the spiroindolone 
pocket (Additional file 1: Figure S3).
That having been said, these results cannot entirely 
rule out spiroindolone-pocket binding. NSC11668 and 
hitachimycin binding to additional targets may be pri-
marily responsible for growth inhibition, such that 
spiroindolone-pocket binding, though legitimate, has lit-
tle biological effect. In the case of hitachimycin, whole-
cell inhibition was more potent than cell-free ScPma1p 
inhibition, supporting this possibility (Additional file  1: 
Figures S1A and S2). We note, also, that the point muta-
tions produced only a twofold reduction in the potency 
of our control compound NITD609, a low-nanomolar 
spiroindolone-pocket-binding ScPma1p inhibitor [17] 
(Additional file  1: Figures S1B and S3C). These issues 
aside, we nevertheless believe that the most likely expla-
nation for our experimental results is that NSC11668 and 
hitachimycin do not bind the spiroindolone pocket.
NSC11668 and hitachimycin are not general, non‑specific 
binders
At sufficiently high concentrations, many small mole-
cules form colloidal aggregates between 100 and 1600 nm 
across. Protein adsorption to colloidal surfaces can lead 
to denaturation. Small-molecule aggregation is thus a 
major cause of non-specific inhibition, often yielding 
false positives in early-stage drug-discovery campaigns.
Nsc11668
We performed a cheminformatics search to verify that 
NSC11668 does not aggregate. First, given that deter-
gent disrupts colloid formation [32, 33], we searched for 
examples of detergent-dependent NSC11668 inhibition. 
If a compound inhibits via aggregation, one would expect 
inhibition in the absence of detergent that is abolished 
when detergent is added. Two biochemical assays cata-
logued in PubChem [34, 35] (AIDs 584 and 585) tested 
for AmpC beta-lactamase inhibition in the presence and 
absence of the detergent Triton X-100 [32], respectively. 
NSC11668 did not inhibit AmpC beta-lactamase in 
either screen, demonstrating that it does not aggregate.
In another screen (AID 624002), NSC11668 inhibited 
mutant isocitrate dehydrogenase 1 in the low-micromo-
lar range, even in the presence of the detergent TWEEN 
20. Similar screens against glucocerebrosidase-p2 (AID 
348) and the thioesterase domain of fatty acid synthase 
(AID 602261) have shown NSC11668 activity in the pres-
ence of detergent. Again, if NSC11668 were a general, 
non-specific inhibitor/aggregator, the detergent should 
have disrupted any colloid formation. These screens simi-
larly demonstrate that NSC11668 is capable of specific 
inhibition.
To further rule out the possibility of general, non-spe-
cific inhibition, we considered all 794 PubChem-cata-
logued screens that included NSC11668 (August, 2017). 
To identify screens that used cell-free assays to measure 
NSC11668 activity against specific proteins, we (1) dis-
carded the screens that did not include a listed target; 
(2) retained only screens that explicitly listed NSC11668 
as active or inactive; (3) and removed screens that con-
tained words in their titles or protocol descriptions that 
suggested a cell-based assay (e.g., “cell-based,” “cell line,” 
“cell suspension,” etc.). NSC11668 inhibited only two of 
the 217 unique proteins that remained. Inhibition of a 
third protein was inconclusive because different screens 
yielded different results. The total hit rate, then, is some-
where between 0.9 and 1.4%. We would expect this rate 
to be higher if non-specific inhibition were at play.
NSC11668 is thus not a general, non-specific inhibitor, 
but it does appear to be promiscuous. Further optimi-
zation will be required to achieve P-type ATPase speci-
ficity. Aside from the targets identified in the cell-free 
assays above, cell-based assays suggest inhibition of the 
TIM22 import pathway, the GLP-1 receptor, HSP90, and 
tyrosyl-DNA phosphodiesterase 1 (see AIDs 493003, 
540268, 540270, 624417, 686978 and 686979). In some 
cases, NSC11668 polypharmacology may be beneficial. 
For example, NSC11668 is also known to inhibit H. sapi-
ens ABCG2 [36], an ABC transporter like those that are 
deleted in the  ABC16-Monster strain. ABCG2 plays roles 
in transporting both xenobiotics [37, 38] and diverse 
endogenous molecules, ranging from heme [39, 40] to 
urate [41] to riboflavin [38]. NSC11668 may therefore 
inhibit its own cellular export, potentiating any pharma-
cological effect.
Hitachimycin
Cheminformatics analyses also suggest hitachimycin is 
capable of specific inhibition. Hitachimycin is active in 
three PubChem-catalogued assays that include aggre-
gation-preventing detergent: AID 652105, against phos-
phatidylinositol 5-phosphate 4-kinase in the presence of 
the detergent CHAPS; and AIDs 1053136 and 743269, 
against HIV-1 LEDGF/p75 DNA integration in the 
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presence of the detergent Brij-35. The compound has 
been studied previously as a possible antibiotic, antifun-
gal, and antitumor agent [42, 43].
A total of 226 screens tested hitachimycin for biologi-
cal activity. Applying the same filters described above, 
we identified 55 potential protein targets. Of these, 
hitachimycin was active against only three (5.5%). We 
would again expect this rate to be higher if hitachimycin 
acted via non-specific inhibition.
NSC11668 and hitachimycin may bind the ScPma1p 
ATP‑binding pocket
NSC11668 and hitachimycin inhibit ScPma1p, but they 
do not bind the ScPma1p spiroindolone pocket. We 
therefore hypothesize that they bind the ScPma1p ATP-
binding pocket, similar to the general ATPase inhibitor 
decavanadate [19]. Our whole-cell and cell-free (vesicle-
based) assays cannot distinguish between ligand binding 
to the different ScPma1p sites, so we turned to homology 
modeling and computer docking. We acknowledge that 
these computational techniques are only predictive, but 
they can be useful tools for hypothesis generation.
Homology modeling
We used a ScPma1p homology model described in detail 
elsewhere [17]. Homology modeling was critical for this 
project because, as a large transmembrane protein, ScP-
ma1p has been difficult to isolate and crystallize. To cre-
ate the ScPma1p model, we used the  Na+,  K+-ATPase 
from Sus scrofa as a structural template (PDB 3N2F, chain 
C) [20]. Per a Clustal Omega alignment [44, 45], these 
two proteins share 27.5% sequence identity (see UniProt 
P05030 and P05024, respectively) [46].
The amino acids that form the ATP binding site are 
even more conserved across the two proteins. We exam-
ined an ADP-bound Sus scrofa  Na+,  K+-ATPase struc-
ture (3WGU:A) [47] and identified 19 pocket-lining 
amino acids that come within 4 Å of the crystallographic 
ADP molecule: T371, D443, S445, E446, F475, S477, 
K480, Q482, K501, G502, A503, R544, V545, L546, T610, 
G611, D612, R685, and N713. Thirteen (68%) of these 
were identical in the two species (S. scrofa vs. S. cerevi-
siae). Additionally, both proteins have negatively charged 
amino acids at residue 446 (glutamic acid vs. aspartic 
acid, respectively) and hydrophobic side chains at residue 
545 (valine vs. alanine, respectively). These ATP-binding-
pocket similarities help justify our use of 3N2F:C as a 
structural template.
The 3N2F-based model captures ScPma1p in the E2P 
(cation-free) conformation. In this conformation,  Mg2+ 
alone is bound, and the cation is accessible to the extra-
cellular space for export. We also modeled ScPma1p in 
the E1P (cation-bound) conformation using a different 
Sus scrofa  Na+,K+-ATPase structure as the template 
(PDBID: 3WGV) [47]. While this second conforma-
tion may prove useful in future ligand-discovery efforts, 
we opted not to pursue it in the present study. Docking 
the ScPma1p inhibitors NITD609 and NITD246 into the 
spiroindolone binding pocket of the 3WGV-based model 
gave seemingly implausible poses. We were therefore 
reluctant to pursue the E1P model further.
Computer docking
To generate binding-mode hypotheses, we used Auto-
Dock Vina [48] to dock NSC11668 and hitachimycin into 
the ATP binding site of our 3N2F-based (E2P) homology 
model. We considered the top-scoring Vina pose for each 
docked compound.
Figure  1a illustrates the predicted molecular interac-
tions between NSC11668 and the ScPma1p ATP-binding 
pocket. The central 1H-pyrazolo[3,4-d]pyrimidine moi-
ety forms a cation-π interaction with R544, and one if the 
chlorobenzene moieties forms a π–π stacking interaction 
with F475. This second interaction is notable because the 
ATP adenine moiety forms a similar π–π stacking inter-
action with F475, per the 3WGU structure [47]. Figure 1b 
illustrates the predicted molecular interactions between 
hitachimycin and the ATP-binding pocket. A compound 
hydroxyl moiety hydrogen bonds with the A545 back-
bone, and the benzene moiety also forms a π–π stacking 
interaction with F475.
Follow‑up whole‑cell studies
We ultimately chose not to pursue hitachimycin fur-
ther as a drug lead. LC–MS analysis determined that 
the hitachimycin sample we obtained from the NCI was 
only 67.3% pure, and the ZINC [49] database identified 
no additional vendors. Hitachimycin was also absent 
from the MolPort database, which includes compounds 
that are commercially available through many suppliers. 
We therefore cannot rule out the possibility that a sam-
ple impurity inhibits ScPma1p rather than hitachimycin 
itself.
In contrast, LC–MS analysis revealed that the 
NSC11668 sample obtained from the NCI was 95.9% 
pure. We therefore considered NSC11668 to be the more 
promising lead. NSC11668 satisfies all of Lipinski’s rules 
for drug-like molecules [50, 51] according to Schroding-
er’s QikProp software [52] (molecular weight: 385.255; 
hydrogen-bond donors: 2; hydrogen-bond acceptors: 
4; predicted LogP: 4.891). NSC11668 possesses a rigid, 
purine-like scaffold similar to that of many other phar-
maceuticals. Indeed, bicyclic compounds with pyrimi-
dine-diamine substructures, e.g., olomoucine [53], H717 
[54], and seliciclib [55], are currently being pursued as 
possible cyclin-dependent kinase inhibitors.
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To further explore the pharmacological potential of 
NSC11668, we verified its activity against whole-cell, 
wild-type S. cerevisiae. The compound is active in the 
low-micromolar range even when S. cerevisiae’s drug 
efflux pumps are intact  (IC50 of 20.3  ±  4.18  μM, see 
Additional file 1: Figure S2, Row C).
We also evaluated NSC11668 for human cellular cyto-
toxicity. NSC11668 had an  IC50 of 22.67 ± 2.77 μM against 
human hepatocarcinoma HepG2. To develop NSC11668 
into an orally available drug, further optimization will be 
required to improve the therapeutic index. However, regard-
less of the potency of this specific compound, NSC11668 
represents a new ScPma1p-inhibiting scaffold class that will 
prove useful in future drug-discovery projects. We also note 
that its  IC50 value is comparable to that of other clinically 
approved antifungals tested in our yeast model (e.g., topi-
cal ciclopirox: ~ 30 μM; oral fluconazole: ~ 3 μM; oral itra-
conazole: ~ 5 μM; topical miconazole: ~ 3 μM). NSC11668 
therefore warrants continued study.
Conclusions
In summary, we have identified NSC11668 and 
hitachimycin as antifungal molecules that target ScP-
ma1p, a transmembrane protein crucial for pH homeo-
stasis in fungal pathogens [14]. We judge NSC11668 to be 
the more promising drug lead.
As expected, NSC11668 showed less efficacy against 
wild-type yeast than against the  ABC16-Monster strain, 
highlighting the strength of the  ABC16-Monster tech-
nique as a tool for identifying novel molecules and tar-
gets. Phenotypic screens against  ABC16-Monster, which 
lacks 16 drug efflux pumps that might otherwise reduce 
intracellular inhibitor concentrations, may identify 
potential drug leads that would be missed in wild-type 
screens. NSC11668 binds to ScPma1p with low-micro-
molar affinity and is therefore a candidate for chemical 
optimization. Even slight modifications to compounds 
can sometimes drastically improve efficacy. KAE261, 
a low-micromolar ScPma1p inhibitor that binds the 
spiroindolone-binding pocket, is one of many examples 
that could be cited. KAE585, which differs from KAE261 
only by the addition of a single halide atom, is 100 times 
more potent against ScPma1p  (EC50 = ~ 100 nM) than is 
KAE261 [17].
An obvious future direction is to improve the potency 
of these compounds against wild-type yeast. Simple 
molecular modifications, especially those aimed at reduc-
ing hydrophobicity [56], can often reduce efflux [57, 58]. 
Cancer drug discovery provides several excellent exam-
ples of this approach. Human ABC transporters such as 
P-gp and MRP1 contribute to chemotherapy resistance, 
but small modifications to anthracycline compounds 
produce compounds such as annamycin with reduced 
export, leading to substantially improved activity against 
multidrug-resistant cancer cells [59]. Peptide-conjugated 
doxorubicin is also effective against doxorubicin-resistant 
cells for the same reason [60]. We therefore believe that 
carefully considered medicinal chemistry may reduce 
NSC11668 efflux as well.
Direct inhibition of ABC transporters is another prom-
ising approach. Holmes et  al. [61] recently used clor-
gyline, an inhibitor of fungal ABC and MFS efflux pumps, 
Fig. 1 Predicting binding poses. a NSC11668 is predicted to bind the ATP‑binding pocket. Its central 1H‑pyrazolo[3,4‑d]pyrimidine moiety may 
form a cation‑π interaction with R544. One if its chlorobenzene moieties may form a π–π stacking interaction with F475, as does ADP in the 3WGU 
structure. b Hitachimycin is similarly predicted to bind the ATP‑binding pocket. One of its hydroxyl moieties may hydrogen bond with the A545 
backbone. Its benzene moiety may also form a π–π stacking interaction with F475
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to reverse azole resistance in yeast. Similarly, Schuetzer-
Muehlbauer et  al. showed that several ABC-transporter 
inhibitors, including terbinafine, propafenones, FK506, 
and GP382, may also function as fungal “chemosensitiz-
ers [62],” as may baicalein [63].
This efflux-inhibitor approach has also been validated 
in other contexts. Verapamil, an L-type calcium chan-
nel blocker already in clinical use, has been shown to 
reduce vincristine resistance in cancer cells by blocking 
ABC transporters [64]. Other cancer chemosensitiz-
ers have also been described [65–67]. Similarly, some 
have hypothesized that ZnO nanoparticles may enhance 
the activity of ciprofloxacin against S. aureus via inhibi-
tion of the NorA efflux protein [68]. It is interesting that 
NSC11668 is itself an ABCG2 inhibitor [36], suggest-
ing that it may sensitize cells to its own ScPma1p activ-
ity. Even if this sensitization is limited, administering 
NSC11668 with an efflux-inhibiting adjuvant may still be 
a promising approach for antifungal therapy.
Methods
Yeast strains
Control strain (strain name SY025)  =  S. cerevi-
siae. Genotype: MATa ho∆::[tetO2pr-GFP, URA3] 
can1∆::GMToolkit-a lyp1∆ his3∆1 leu2∆0 ura3∆0 
met15∆0. PMA L290S and PMA1 P339T have been 
described previously [17].
ABC16-Monster  =  S. cerevisiae Genotype: MATa 
adp1∆ snq2∆ ycf1∆ pdr15∆ yor1∆ vmr1∆ pdr11∆ nft1∆ 
bpt1∆ ybt1∆ ynr070w∆ yol075c∆ aus1∆ pdr5∆ pdr10∆ 
pdr12can1∆::GMToolkit-a lyp1∆ his3∆1 leu2∆0 ura3∆0 
met15∆0 (deletions for the ABC transporter genes are 
marked with [tetO2pr-GFP, URA3]).
Whole‑cell yeast assays
For all yeast growth assays, S. cerevisiae was obtained 
from frozen stocks. Cultures were established using cells 
taken from single colonies grown on agar plates and inoc-
ulated into 2 mL of YPD in 5 mL snap-cap culture tubes. 
The tubes were grown overnight at 250 RPM in a shak-
ing incubator at 30 °C (Controlled Environment Incuba-
tor Shaker, Model G-25, New Brunswick Scientific Co., 
Inc.). Cultures were extracted during the mid-log growth 
phase, as judged by an OD600 (600 nm) reading between 
0.1 and 0.5. The cells were then diluted in YPD to OD600 
0.1 and then again 10× in YPD for a final OD600 of 0.01.
For the whole-cell sensitivity assay, cells at OD600 0.01 
were plated onto a 96-well plate with a volume of 100 μL. 
The compounds of the NCI Diversity Set IV were trans-
ferred using a 96 Pin Replicator (Thermo Scientific Nunc) 
that had been sterilized with 70% ethanol and flamed with 
a Bunsen burner. The final NCI-compound concentration 
was 100 μM. The replicator was submerged in DI water, 
stamped with the NCI Diversity Set IV plate, and released 
into a 96-well plate with  ABC16-Monster cells. After an 
initial reading of OD600 using a Synergy HT spectro-
photometer, plates were covered with a lid and placed in 
an incubator at 30 °C for 18 h. Following incubation, the 
plates were shaken for 1  min on the “high” setting and 
immediately read at OD600. Sensitivity was determined 
by comparing growth relative to a DMSO control.
For the  IC50 assays, cells at OD600 0.01 were transferred 
to a 96-well plate (final OD600  =  0.01). At least three 
independent biological replicates of technical duplicates 
were used to calculate the  IC50 in each experiment. Eight 
two-fold serial dilutions were performed with a top con-
centration of 150 μM. After an initial reading of OD600 
using a Synergy HT spectrophotometer, plates were cov-
ered with a lid and placed in an incubator at 30 °C for 18 h. 
Following incubation, the plates were shaken for 1 min on 
the “high” setting and immediately read at OD600.
OD600 values at time 0 (h) were subtracted from 
OD600 values at time 18  h. Nonlinear regression on 
log(inhibitor) versus response with variable slope (four 
parameters) was performed using Graphpad Prism, 
which determined the  IC50 value for each pair of techni-
cal duplicates, with minimum values constrained to 0.0. 
These  IC50 values were then averaged across each of the 
biological replicates.
ScPma1p ATPase assay
In this vesicle-based assay, ATP hydrolysis was assayed 
at 30 °C in 0.5 mL of an ATP regenerating system (5 mM 
phosphoenolpyruvate and 50  μg/mL pyruvate kinase), 
50 mM MES/Tris pH 6.25, 5 mM  NaN3, 5 mM  Na2 ATP 
(Roche), and 10 mM  MgCl2. Fiske and Subbarow reagent 
[69] was used to terminate the reaction after 20 min. Fol-
lowing an additional 45  min of color development, the 
release of inorganic phosphate was measured as absorp-
tion at 660 nm. Full details can be found in Ref. [17].
HepG2 cytotoxicity assay
HepG2-A16-CD81EGFP, i.e., human hepatocarcinoma 
HepG2 cells stably transformed to express the tetraspa-
nin CD81 receptor [70, 71], were cultured at 37 °C in 5% 
 CO2 in DMEM (Life Technologies, CA) supplemented 
with 10% FBS, 0.29 mg/ml glutamine, 100 unit penicillin, 
and 100 μg/mL streptomycin. For the HepG2 cytotoxic-
ity assays, 3  ×  103 of the HepG2-A16-CD81EGFP cells 
in 5  μl of assay medium (DMEM without Phenol Red, 
5% FBS, and 5x Pen Strep Glutamine; Life Technolo-
gies, CA) at 6 ×  105 cells/ml were seeded in 1536-well 
plates (Greiner BioOne white solid bottom custom GNF 
mold). Compounds were prepared in 12-point 1:3 serial 
dilutions in DMSO, with the top concentration start-
ing at 10 mM. 50 nl of the compounds in DMSO (0.5% 
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final DMSO concentration per well) were transferred 
with Acoustic Transfer System (ATS) (Biosero) into the 
assay plates. Puromycin (12-point serial dilution start-
ing at 10 μM) and 0.5% DMSO were used as positive and 
negative controls, respectively. After incubation at 37 °C 
for 72  h, HepG2 cytotoxicity was assessed by removing 
the media via an inverted spin of the plates at 150 g for 
30  s, followed by the addition of 2 μL CellTiterGlo rea-
gent (Promega diluted 1:2 with deionized water) per well 
using the MicroFlo liquid handler (BioTek). Immediately 
after the addition of the luminescence reagent, the plates 
were vortexed for 10 s and read with an EnVision Multila-
bel reader (PerkinElmer).  IC50 values were obtained using 
the normalized bioluminescence intensity and a non-
linear variable-slope four-parameter regression curve-
fitting model in Prism 6 (GraphPad Software Inc).
Homology modeling
The homology model has been described in detail else-
where [17]. In brief, the model was built with Schröding-
er’s Prime software [72] using the UniProt [46] sequence 
P05030 and a structure of a homologous sodium–potas-
sium pump from Sus scrofa (PDBID: 3N2F, chain C) [20]. 
Schrödinger’s knowledge-based method was used, fol-
lowed by refinement with the Protein Preparation Wizard 
[73]. The resulting PDB file was converted to AutoDock 
Vina’s PDBQT format using AutoDockTools [74].
Virtual screening
Three-dimensional small-molecule models of NSC11668 
and hitachimycin (NSC343256) were prepared using 
Schrodinger’s LigPrep module. Epik [75] assigned pro-
tonation states at pH values ranging from 5.0 to 9.0. 
No more than one low-energy ring conformation was 
selected for each compound, alternate tautomeric states 
were considered, and all chiralities were varied except for 
those specified in the initial structures, allowing at most 
32 variations per molecule. Geometries were relaxed 
using the OPLS_2005 forcefield [76, 77]. The resulting 
SDF models were converted to AutoDock Vina’s PDBQT 
format using Open Babel [78] and AutoDockTools [74].
NSC11668 and hitachimycin were docked into ScPma1p 
using AutoDock Vina [17]. The docking box measured 30 
Å × 30 Å × 30 Å, centered on the ATP-binding pocket. The 
default Vina “exhaustiveness” parameter was used (eight).
Additional file
Additional file 1: Table S1. A list of additional antifungal compounds 
found in our whole‑cell screen. Figure S1.  IC50 curves for the cell‑free, 
vesicle‑based ScPma1p assays. Figure S2.  IC50 curves for the whole‑
cell assays. Figure S3. Compound  IC50 values against whole‑cell 
 ABC16‑Monster yeast, with and without two distinct spiroindolone‑bind‑
ing‑pocket ScPMA1 mutations (L290S and P399T).
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